Mesenchymal Stem Cells for Alzheimer's Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this research study is to test if adding one infusion of mesenchymal stem cells to the current treatment with antipsychotic medication may help control behavioral problems in people with a diagnosis of moderate to severe Alzheimer's disease.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it does require that you have been on antipsychotic medication for at least 4 weeks before the stem cell infusion.
Is the treatment with mesenchymal stem cells generally safe for humans?
How is the mesenchymal stem cell treatment for Alzheimer's disease different from other treatments?
This treatment uses mesenchymal stem cells, which are special cells that can develop into different types of cells and help repair damaged tissues. Unlike traditional Alzheimer's treatments that mainly focus on symptoms, this approach aims to improve brain function and memory by promoting brain repair and reducing harmful proteins. It can be administered directly into the brain or through the bloodstream, offering flexibility in treatment delivery.34567
What data supports the effectiveness of the treatment hMSC for Alzheimer's disease?
Research shows that mesenchymal stem cells (a type of cell that can develop into different types of cells) have improved memory and neurological function in animal models of Alzheimer's disease. These studies suggest that this treatment might help with Alzheimer's by improving brain function and reducing inflammation.34568
Who Is on the Research Team?
Bernard Baumel, MD
Principal Investigator
University of Miami
Are You a Good Fit for This Trial?
This trial is for adults aged 55-90 with moderate to severe Alzheimer's, experiencing behavioral issues. They must be on antipsychotic meds for at least 4 weeks and have a caregiver involved. Excluded are those with uncontrolled conditions like hypertension, recent heart attacks, other dementias, substance abuse history, certain infections or cancers within 3 years.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive one infusion of hMSC in addition to their current antipsychotic medication
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- hMSC
Find a Clinic Near You
Who Is Running the Clinical Trial?
Bernard (Barry) Baumel
Lead Sponsor